95261-39-5

Basic information

• Product Name: 4-aMino-4-phenylcyclohexanone
• Synonyms: 4-aMino-4-phenylcyclohexanone;4-amino-4-phenylcyclohexan-1-one
• CAS NO: 95261-39-5
• Molecular Formula: C₁₂H₁₅NO
• Molecular Weight: 189.2536
• Mol File: 95261-39-5.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-aMino-4-phenylcyclohexanone(CAS DataBase Reference)
• NIST Chemistry Reference: 4-aMino-4-phenylcyclohexanone(95261-39-5)
• EPA Substance Registry System: 4-aMino-4-phenylcyclohexanone(95261-39-5)

Safety Data

• Hazardous Substances Data: 95261-39-5(Hazardous Substances Data)

Upstream product

• 79741-43-8 8-phenyl-1,4-dioxaspiro[4.5]decan-8-amine 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 861857-71-8 2-methyl-propane-2-sulfinic acid (1,4-dioxa-spiro[4.5]dec-8-ylidene)-amide 
• 75945-91-4 4-oxo-1-phenylcyclohexanecarboxylic acid 

Downstream Products

• 1708113-43-2 ACY-1083 
• 479195-00-1 2-(3,5-bis-trifluoromethyl-phenyl)-hex-5-enoic acid (4-oxo-1-phenyl-cyclohexyl)-amide 
• 374791-58-9 (RS)-N-(4-oxo-1-phenylcyclohexyl)-α-(2-propenyl)-3,5-bis(trifluoromethyl)benzeneacetamide 
• 374791-09-0 N-(4-Oxo-1-phenylcyclohexyl)-3,5-bis(trifluoromethyl)benzeneacetamide 
• 374791-63-6 α,α-dimethyl-N-[4-oxo-1-phenylcyclohexyl]-3,5-bis(trifluoromethyl)benzeneacetamide 
• 374791-10-3 (RS)-α-methyl-N-[4-oxo-1-phenylcyclohexyl]-3,5-bis(trifluoromethyl)benzeneacetamide 

Relevant articles and documents

Histone Deacetylase 6 Selective Inhibitors for the Treatment of Cisplatin-Induced Peripheral Neuropathy

Disclosed are methods for treating cisplatin-induced peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a histone deacetylase 6 selective inhibitor.

TREATMENT OF POLYCYSTIC DISEASES WITH AN HDAC6 INHIBITOR

An HDAC6-specific inhibitor (i.e., a compound of Formula I or II) is shown to reduce the pathogenesis associated with polycystic disease. Administration of an HDAC6-specific inhibitor attenuated many of the symptoms characteristic of polycystic liver disease including cyst formation, cyst growth and cholangiocyte proliferation. Treatment with a HDAC6-specific inhibitor also increased the amount of bile duct acetylated tubulin and β-catenin phosphorylation and/or acetylation while reducing bile duct β-catenin synthesis. These results demonstrate that HDAC6 is overexpressed in cystic cholangiocytes and that its pharmacological inhibition reduces cholangiocyte proliferation and cyst growth.

4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I): wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).